ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AKRO Akero Therapeutics Inc

23.98
-0.64 (-2.60%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Akero Therapeutics Inc NASDAQ:AKRO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.64 -2.60% 23.98 23.20 36.00 24.46 23.45 24.20 559,519 05:00:02

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

08/05/2024 12:00pm

GlobeNewswire Inc.


Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Akero Therapeutics Charts.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero TherapeuticsAkero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as two ongoing Phase 3 clinical trials, the SYNCHRONY Histology study in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with MASH (F1-F3 fibrosis) or MASLD. A third clinical trial, the SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4 fibrosis), is expected to be initiated in the second quarter of 2024. The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information.

Investor Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina.tartaglia@sternir.com

Media Contact:Sarah O’Connell732.456.0092soconnell@vergescientific.com

1 Year Akero Therapeutics Chart

1 Year Akero Therapeutics Chart

1 Month Akero Therapeutics Chart

1 Month Akero Therapeutics Chart

Your Recent History

Delayed Upgrade Clock